Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer Supply Gabapentin Related Intermediates: Gabapentin CAS 60142-96-3 1,1-Cyclohexanediacetic Acid (CDA) CAS 4355-11-7 Gabapentin-Lactam (CDI) CAS 64744-50-9 1,1-Cyclohexanediacetic Anhydride (CAA) CAS 1010-26-0 3,3-Pentamethylene Glutarimide (CAI) CAS 1130-32-1 1,1-Cyclohexanediacetic Acid Monoamide (CAM) CAS 99189-60-3| Item | Specifications |
| Appearance | White Crystalline Powder |
| Purity / Analysis Method | >99.5% (HPLC) |
| Melting Point | 167.0~175.0℃ |
| Loss on Drying | <1.00% |
| Residue on Ignition | <0.30% |
| Single Impurity | <0.50% |
| Total Impurities | <1.00% |
| Heavy Metals | <20ppm |
| Test Standard | Enterprise Standard |
| Usage | Intermediate of Gabapentin (CAS: 60142-96-3) |
Description:
Specifications:
Package & Storage:
| Chemical Name | 3,3-Pentamethylene Glutarimide |
| Synonyms | CAI; 3,3-Pentamethylene-2-Pyrrolidoinone; 3-Azaspiro[4.5]decan-2-one; 3-Azaspiro(5,5)undecan-2,4-dione |
| CAS Number | 1130-32-1 |
| CAT Number | RF-PI1244 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C10H15NO2 |
| Molecular Weight | 181.23 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
3,3-Pentamethylene Glutarimide (CAI) (CAS: 1130-32-1) is an intermediate of Gabapentin (CAS: 60142-96-3). Gabapentin is a second- generation antiepileptic drug (AED) known under the proprietary brand name of Neurontin® (Pfizer, New York, NY) in the UK and USA, used as an anticonvulsant. Amino acid structurally related to γ-Aminobutyric Acid (GABA), designed to cross the blood brain barrier. Gabapentin is an anticonvulsant that is chemically unrelated to any other anticonvulsant or mood regulating medication. Gabapentin has an inhibitory effect on partial seizures and subsequent systemic tonic-clonic seizures. Additional treatment for partial seizures that cannot be satisfactorily controlled or tolerated with conventional anticonvulsants, either alone or in combination, and for subsequent systemic seizures.
